| |
|
Licensing and InvestmentSuitably qualified investors who wish to invest in HVL should contact our Corporate Director, Michael Stallibrass, at information@hav-vaccines.com HVL will only consider investments of £50,000 or more HVL plans to license the animal health rights and, separately, the human health rights to appropriate international healthcare companies who can complete the clinical development and commercialise the vaccines on a major regional or global basis. Interested parties should contact Michael Stallibrass, at information@hav-vaccines.com For further information about the vaccine and its development, please contact our Chief Scientific and Medical Officer, Prof John Hermon-Taylor, at information@hav-vaccines.com |
 |
|
